VIRONIKA ESTABLISHES PRESENCE AT SCIENCE CENTER IN PHILADELPHIA

Vironika, LLC, has moved its biology lab to the University City Science Center in Philadelphia.

“This move will allow us to establish a more prominent presence in the Philadelphia scientific biotech community, expand our team of scientists, and continue our efforts in developing novel therapies in cancer and other disease indications” says Pieter van den Heuvel, Ph.D., Program Director.  “We are very pleased with our new location, and positions Vironika to leverage the great resources offered by the Science Center, which not only includes the scientific infrastructure but also the valuable network of other successful biotech companies and investors".

Vironika, LLC, is a privately held company founded in 2009 by Paul Lieberman, Ph.D., from the Wistar Institute.

VIRONIKA SECURES PHASE I SBIR FUNDING FROM NIH TO DEVELOP INHIBITORS FOR EBV LYTIC REACTIVATION

Vironika, LLC, secured a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop a small molecule inhibitor for Epstein-Barr Virus (EBV) lytic reactivation.

“We are thrilled to receive funding for the development of an inhibitor for EBV lytic reactivation, an important aspect in virus-dependent tumor formation,” says Pieter van den Heuvel, Ph.D., Program Director.

The grant will allow Vironika to follow up on initial screening for inhibitors of EBV lytic reactivation, and develop lead compounds that show great efficacy and specificity in biochemical, cellular and in vivo assays.

Vironika, LLC, is a privately held company founded in 2009 by Paul Lieberman, Ph.D.  Dr. Lieberman is a full Professor at the Wistar Institute in Philadelphia.

VIRONIKA RECEIVES PHASE I SBIR GRANT FROM NIH TO DEVELOP A NOVEL STABLE AND TUNABLE GENE THERAPY

Vironika, LLC, received a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop a novel delivery system for gene therapy.

“We are very excited to have secured funding for the development of a novel gene therapy delivery system utilizing our expertise and resources in virology,” says Pieter van den Heuvel, Ph.D., Program Director.

The grant will allow Vironika to develop a novel delivery system for gene therapy, superior to current systems due to specific viral components which will allow for more stable and tunable gene expression.

 

Vironika, LLC, is a privately held company founded in 2009 by Paul Lieberman, Ph.D.  Dr. Lieberman is a full Professor at the Wistar Institute in Philadelphia.

 

VIRONIKA RECEIVES PHASE II SBIR GRANT FROM NIH TO CONTINUE THE DEVELOPMENT OF EBV LATENCY INHIBITORS.

Vironika, LLC, received a Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to continue its efforts to identify small molecules that will inhibit Epstein-Barr Virus (EBV).

“We are very excited to be able to optimize our lead compounds,” says Pieter van den Heuvel, Ph.D., Program Director.  “This highly competitive grant is indicative of the quality and results of our EBV drug discovery and the enthusiasm of the scientific review committee for this approach to eradicating EBV-related malignancies.”

The grant will allow Vironika to further develop and test compounds related to the lead compounds the company has already identified and test them in cell-based assays and xenograft tumor models.


Vironika, LLC, is a privately held company founded in 2009 by Paul Lieberman, Ph.D.  Dr. Lieberman is a full Professor at the Wistar Institute in Philadelphia.